Clinical trials: LDL Cholesterol
Cardiovascular Diseases, Hypercholesterolemia
Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)
Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with LDL-cholesterol values > 115 mg/dl and not…
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Prediabetic State, Overweight and Obesity
- Trial name
- NCT06481020
- Testing
- Plant sterols 2g/day
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Valencia
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Hypercholesterolemia
Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with…
- Trial name
- NCT00653523
- Testing
- Ezetimibe, Simvastatin
- Volunteers
- 151 people
- Sponsor
- Organon and Co
Hypercholesterolemia
The Effects of Lowering Low-density Lipoprotein Cholesterol Levels to New Targets on Cardiovascular Complications in Peritoneal Dialysis Patients
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in dialysis patients. Although significant improvements have been made in the management of CVD in the general population, it is not known whether these…
- Trial name
- NCT00999453
- Testing
- LDL-cholesterol
- Where
- 2 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Clinical Research Center for End Stage Renal Disease, Korea
Atherosclerosis
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis
Recent evidence on the use of statin therapy indicates the potential for ultra-low levels of low-density lipoprotein (LDL-C) to provide greater protection from recurrent coronary heart disease (CHD) events.
- Trial name
- NCT00397657
- Testing
- extended release niacin, ezetimibe
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Walter Reed Army Medical Center
Cardiovascular Diseases
Effect of a Black Garlic Extract on Cholesterol LDL Levels
One of the most characteristic components of the Mediterranean diet is garlic (Allium sativum L.), food to which has been attributed protective properties against cardiovascular diseases (CVD).
- Trial name
- ESACTIVO (NCT04010565)
- Testing
- Aged black garlic extract
- Where
- Spain
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Technological Centre of Nutrition and Health, Spain
Dyslipidemia
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
- Trial name
- NCT06742853
- Testing
- AZD0780, Ezetimibe, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myocardial Infarction
AIDAVA G1 LDL-C Substudy Protocol
This retrospective substudy describes low-density lipoprotein cholesterol (LDL-C) changes and treatment-target attainment among patients with previous myocardial infarction who participated in the AIDAVA first-generation (G1)…
- Trial name
- NCT07839845
- Where
- Estonia
- Volunteers
- 37 people
- Sponsor
- North Estonia Medical Centre
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥ 100 mg/dL (≥…
- Trial name
- NCT01288443
- Testing
- Alirocumab, Atorvastatin
- Where
- 38 sites in United States
- Volunteers
- 183 people
- Sponsor
- Sanofi
Hypercholesterolemia
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy
- Trial name
- NCT03427710
- Testing
- CiVi007
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Civi Biopharma, Inc.
Hypercholesterolemia
Safety and Efficacy of Propionate for Reduction of LDL Cholesterol
The objective of the trial is to evaluate a potential impact of food supplements with the short chain fatty acid propionate on blood LDL cholesterol level.
- Trial name
- PROPER-LDL (NCT03590496)
- Testing
- Calcium-Propionate 500mg
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Charite University, Berlin, Germany
LDL Cholesterol, Triglycerides
Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.
- Trial name
- NCT01028274
- Testing
- Investigational Product 1, Investigational Product 2
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Nordic Pharma, USA
Hypercholesterolemia
Combination of AB-LIFE Probiotic Plus Monacolin K to Reduce Blood Cholesterol
This randomized study evaluates the effectiveness of a nutraceutical combining billion colony forming units (cfu) of three L. plantarum strains (CECT7527, CECT7528 and CECT7529) and 10 mg of monacolin K in reducing blood…
- Trial name
- NCT04677335
- Testing
- AB-LIFE with Monacolin K
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
Hypercholesterolemia, Coronary Heart Disease
Addition of Phytosterols to a Low Phytosterol Diet
Studies have shown that phytosterols will lower LDL cholesterol. Typical diets can contain between 250 to 500 mg of naturally-occurring phytosterols.
- Trial name
- phyteaux-I (NCT00860054)
- Testing
- Different amount of phytosterols are added into diets
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
ACS (Acute Coronary Syndrome), Hyperlipidemia
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual…
- Conditions
- ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level
- Trial name
- EHR-LOCALE (NCT07685639)
- Testing
- Pharmacist-led lipid optimization pathway
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- University of Alberta
Dyslipidemia Associated With Type II Diabetes Mellitus
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT07359105
- Testing
- Moderate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
- Where
- 2 sites in South Korea
- Volunteers
- 2,186 people
- Sponsor
- Sin Gon Kim
Hyperlipemia, Mixed, ASCVD
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values.
- Trial name
- LDL-ALERT (NCT05088759)
- Testing
- Alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk
LDL Cholesterol Reduction Following Ezetimibe Initiation
This clinical trial will study why some people have a larger drop in low-density lipoprotein cholesterol (LDL-C), known as "bad cholesterol," after starting ezetimibe.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
- Trial name
- EZE-TRACK (NCT07839741)
- Testing
- Ezetimibe
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Universidade do Porto
Hyperlipidemia
Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol
A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight…
- Trial name
- MBX-8025 (NCT00701883)
- Testing
- MBX-8025, Atorvastatin
- Where
- 28 sites in United States
- Volunteers
- 183 people
- Sponsor
- Gilead Sciences